Newsletter | January 18, 2023

01.18.23 -- Anatomy Of A Biopharma VC Deal

New Podcast Episode
Featured Articles
Peter Marks: Prioritizing Better Communication And Faster Product Reviews

In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drug makers.

Anatomy Of A Biopharma VC Deal

Ray Therapeutics CEO Paul Bresge and 4BIO Capital Managing Partner Dmitri Kuzmin, Ph.D., break down the deal that launched Ray and ponder the risk of a mission-driven biopharma CEO.

What I Learned As CEO The First Time Around

Less than 10% of novel compounds that enter Phase 1 clinical trials obtain FDA approval, which is why we followed a detailed road map for budgeting and advancing our new therapy at each stage of development.

Web-Exclusive Content
4 Strategies For Recruiting & Retaining A Diverse, Well-Trained Workforce

The projected growth of the clinical research industry demands that the workforce keep pace with the workload — and it must be diverse and research-ready. What’s at stake? Nothing more than the risk of delaying approvals of new treatments for patients who need them.

Industry Insights
What Life Sciences Companies Need To Know In 2023

Learn how the use of real-world data supports regulatory decisions and approvals, and personalized treatments through digital technologies and therapies, while maximizing value and efficiency with data and analytics.

How Collaborative Value Engineering And Continuous Improvement Enhance The CDMO Relationship

Regular assessments of a partnership’s value in terms of supply chain, operational efficiency, data analysis, and more can optimize and extend the product life cycle.

The Rise Of Decentralized Clinical Trials

Discover how technological advancements have created the Internet of Things (IoT), in which numerous devices, including wearables like fitness trackers, can all be connected through software and cloud computing. 

Nasal Delivery Technology, QbD Processes, And Outsourcing

Understand the advantages of unit/bi-dose nasal delivery technology, application of QbD processes for inhaled product development, and why to outsource inhalation development and manufacturing.

Digital Edition
January 2023 Digital Edition

Inside you will find more on:

  • Industry Research
  • Why Founder CEOs Deliver
  • Leadership Lessons
  • Avoiding Trade Secret Lawsuits

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.